After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that atai Life Sciences Appoints Anne Johnson as Chief Financial Officer.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
ATAI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of ATAI Life Sciences N.V. is $305.46M. A total of 1.15 million shares were traded on the day, compared to an average of 1.31M shares.
In the most recent transaction, Brand Florian bought 20,000 shares of ATAI for 1.16 per share on Nov 16. After the transaction, the insider now owns 130,000 company shares. In a previous transaction on Sep 13, Brand Florian bought 40,000 shares at 1.45 per share. ATAI shares that the insider owns now total 110,000.
Among the insiders who bought shares, Apeiron Investment Group Ltd. acquired of 1,214,297 shares on Mar 29 at a per-share price of $1.32. This resulted in the 10% Owner holding 32,086,697 shares of ATAI after the transaction. In another insider transaction, Brand Florian bought 70,000 shares at $1.48 per share on Mar 29. Company shares held by the insider now total 70,000.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ATAI in the last 3 months, the mean price target is $14.50 with high estimates of $21.00 and low estimates of $6.00. In terms of 52-week highs and lows, ATAI has a high of $2.39 and a low of $1.02.
As of this writing, ATAI has an earnings estimate of $BioXcel Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of ATAI Life Sciences N.V. estimates, with a high estimate of $RTAI per share and a lower estimate of $ATI Inc.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ATAI’s latest balance sheet shows that the firm has $362.27M in Cash & Short Term Investments as of fiscal 2021. There were $743.00k in debt and $20.93M in liabilities at the time. Its Book Value Per Share was $1.60, while its Total Shareholder’s Equity was $385.96M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ATAI is Buy with a score of 4.60.
